A method is disclosed for determining whether a compound binds to a lipoprotein
such as LDL or VLDL in a manner which will lower plasma cholesterol. The method
provided includes assessing the ability of the compound to form a complex with
the lipoprotein, and then determining whether the newly formed complex causes a
change in the structure of apoB-100 that results in increased binding affinity
to an LDL receptor.
